AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Deferred Revenue · Q3 FY2025 · quarter ended Sep 2025
Deferred revenue of €1.69M in Q3 FY2025
Q3 FY2025 deferred revenue was €1.69M.
Context
- Deferred revenue amounted to 1.0% of total assets at the end of Q3 FY2025.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
Currency unavailable · from the balance sheet
No Deferred Revenue data reported for this period type.
Deferred Revenue vs competitors
How AGMB compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue is compared through growth and share of total assets rather than absolute size.
- Deferred revenue amounts to 1.0% of total assets for AGMB, versus a peer median of 0.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $6.67M USD | — | — | 1.2% |
| Mar 2026 | $3.97M USD | — | — | 2.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €1.69M EUR | — | — | 1.0% |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | -100.0% | — | 0.6% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.